Here are five things to know:
1. Northland Securities will now cover K2M.
2. The company issued an “outperform” rating.
3. The price objective on the stock is $31.
4. Barclays also raised K2M’s price target from $27 to $28.
5. K2M’s market cap is $988.2 million.
More articles on orthopedic devices:
LDR gets “Outperform” rating—5 key notes
Spinal Kinetics M6 disc replacement: Grood results 2 years postop
Allegheny Health Network incorporates MAKOplasty
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.